Whither Generics? Five Opinions
Executive Summary
A few years ago, generics looked unstoppable; today, pricing's reached suicidal levels. As for generic substitution, patients would rather fight than switch.
You may also be interested in...
Octave Biosciences Takes It Up Another Semitone With Michael J Fox Foundation Grant
The diagnostics company has secured $10m from the foundation to develop a biomarker test for Parkinson’s disease.
What’s Next? Five Things To Look Out For In December
Generics Bulletin previews the most noteworthy and anticipated events for December 2023.
Member States Want Action Over High-Risk IVDs And Eudamed Medical Device Database
After some 10 years of the implementation of the EU’s Medical Device and IVD Regulations being an annual agenda item at December Council of the EU meetings, the scale of problems remains the same.